相关实验视频
Updated: Jan 18, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
23.0K
奥本图祖马布诱导的严重急性血小板缺血:一个病例报告和文献综述
Kun Kou1, Qiaolin Zhou1, Lijun Du1
1Department of Haematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Frontiers in immunology
|September 8, 2025
概括
用于B细胞淋巴瘤的奥比努祖马布可以导致罕见但严重的急性血小板缩. 这一案例凸显了在治疗期间需要对这种危及生命的副作用进行认识和管理的必要性.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 免疫治疗是一种免疫疗法.
背景情况:
- 奥本图祖马布是一种II型抗CD20单克隆抗体,用于B细胞淋巴瘤,如卵泡淋巴瘤 (FL) 和慢性淋巴细胞白血病 (CLL).
- 临床研究表明,在与化疗相结合时,与rituximab相比,obinutuzumab可以改善无进展生存率.
- 副作用包括输液反应,骨髓抑制和感染;然而,Obinutuzumab诱导的急性血栓缩 (OIAT) 很少报告,尤其是严重的病例.
研究的目的:
- 报告一个严重的急性obinutuzumab诱导的血小板缺血 (OIAT) 的病例.
- 审查有关OIAT管理的现有文献.
- 为了提高人们对这种罕见而危及生命的并发症的认识.
主要方法:
- 一个28岁的男性患有IV期FL的病例报告.
- 患者接受了R-CHOP化疗,随后进行了奥比努图祖马布维持疗法.
- 在obinutuzumab治疗期间监测血小板计数.
主要成果:
- 患者在欧比努祖马布单独治疗的第三天出现了严重的急性血小板缺血 (血小板数下降到2×10^9/L).
- 严重的血小板缺血在随后的奥比努图祖马布应用中复发.
- 这表明可能与obinutuzumab相关的重大不良事件.
结论:
- 奥比努祖马布诱导的急性血小板缺血 (OIAT) 是一种罕见但可能致命的并发症.
- 医疗保健提供者应警在接受obinutuzumab的患者中OIAT.
- 为了有效的管理策略,需要进一步的研究和意识.
相关概念视频
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Blood Transfusion and Agglutination
14.0K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
14.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Acute Kidney Injury III: Clinical Manifestations
828
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
828
Venous Thrombosis IV: Nursing Management
202
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
202
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
597
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
597

